{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:50Z","timestamp":1792896170643,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Bisphosphonates and denosumab prevent bone complications in patients with bone metastases from solid tumours. This retrospective, longitudinal, cohort study provides data on their real-world use in this setting in Germany.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Adults with bone metastases from breast, prostate or lung cancer who were newly initiated on a bisphosphonate or denosumab between 1 July 2011 and 31 December 2015 were identified from a German healthcare insurance claims database. Primary outcomes included persistence, compliance, discontinuation and switch rates at 12\u00a0months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>This study included 1130 patients with bone metastases: 555 (49%) had breast cancer, 361 (32%) prostate cancer and 242 (21%) lung cancer. Mean age was 65\u00a0years for patients with breast or lung cancer and 74\u00a0years for those with prostate cancer. Across all tumour types, compared with any bisphosphonate, 12-month persistence was higher with denosumab (breast cancer 78% vs 54\u201358%, prostate cancer 58% vs 50%, lung cancer 68% vs 34\u201360%), median time to discontinuation was longer with denosumab and switch rates were lower for denosumab (breast cancer 5% vs 14\u201319%, prostate cancer 2% vs 11%, lung cancer 3% vs 7\u201312%). Compliance at 12\u00a0months was longer for denosumab than for any bisphosphonate in breast cancer (75% vs 42\u201348%) and in prostate cancer (47% vs 36%).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Patients initiated on denosumab following a diagnosis of bone metastases from breast, prostate or lung cancer had greater medication persistence, longer time to discontinuation, improved compliance and lower switch rates than those initiated on a bisphosphonate.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00520-020-05357-5","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T18:04:08Z","timestamp":1582308248000},"page":"5223-5233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-1909","authenticated-orcid":false,"given":"Ingo","family":"Diel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Ansorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Giannopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Niepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Intorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"5357_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","volume":"115","author":"JJ Body","year":"2017","unstructured":"Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J (2017) Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol 115:67\u201380. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.04.008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"5357_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2010.227","volume":"7","author":"LJ Suva","year":"2011","unstructured":"Suva LJ, Washam C, Nicholas RW, Griffin RJ (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7(4):208\u2013218. https:\/\/doi.org\/10.1038\/nrendo.2010.227","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"5357_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franz\u00e9n L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland \u00d8S, Sartor O (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"5357_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","volume":"9","author":"RE Coleman","year":"2004","unstructured":"Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14\u201327. https:\/\/doi.org\/10.1634\/theoncologist.9-90004-14","journal-title":"Oncologist"},{"issue":"suppl_3","key":"5357_CR5","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body J, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 25(suppl_3):iii124\u2013iii137","journal-title":"Ann Oncol"},{"issue":"3","key":"5357_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00520-015-2908-1","volume":"24","author":"R von Moos","year":"2016","unstructured":"von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y (2016) Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer 24(3):1327\u20131337. https:\/\/doi.org\/10.1007\/s00520-015-2908-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"5357_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162\u2013167. https:\/\/doi.org\/10.1016\/j.juro.2010.03.034","journal-title":"J Urol"},{"issue":"2","key":"5357_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","volume":"129","author":"M Yong","year":"2011","unstructured":"Yong M, Jensen AO, Jacobsen JB, Norgaard M, Fryzek JP, Sorensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129(2):495\u2013503. https:\/\/doi.org\/10.1007\/s10549-011-1475-5","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5357_CR9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3111\/13696998.2016.1150852","volume":"19","author":"J Pereira","year":"2016","unstructured":"Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R (2016) Cost of skeletal complications from bone metastases in six European countries. J Med Econ 19(6):611\u2013618. https:\/\/doi.org\/10.3111\/13696998.2016.1150852","journal-title":"J Med Econ"},{"issue":"3","key":"5357_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clbc.2011.03.015","volume":"11","author":"HT Hatoum","year":"2011","unstructured":"Hatoum HT, Lin S-J, Smith MR, Guo A, Lipton A (2011) Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer 11(3):177\u2013183","journal-title":"Clin Breast Cancer"},{"key":"5357_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2407-11-29","volume":"11","author":"AO Jensen","year":"2011","unstructured":"Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT (2011) Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 11:29. https:\/\/doi.org\/10.1186\/1471-2407-11-29","journal-title":"BMC Cancer"},{"issue":"suppl 3","key":"5357_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S (2013) NCCN task force report: bone health in cancer care. J Natl Compr Cance Netw 11(suppl 3):S1\u2013S50","journal-title":"J Natl Compr Cance Netw"},{"issue":"Suppl 3","key":"5357_CR13","first-page":"S1","volume":"7","author":"JR Gralow","year":"2009","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cance Netw 7(Suppl 3):S1\u2013S32","journal-title":"J Natl Compr Cance Netw"},{"key":"5357_CR14","unstructured":"European Medicines Agency (2018) Zometa (zoledronic acid for injection). Summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/zometa-epar-product-information_en.pdf. Accessed 30 Jan 2020"},{"key":"5357_CR15","unstructured":"European Medicines Agency (2018) XGEVA (denosumab). Summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/xgeva-epar-product-information_en.pdf. Accessed 30 Jan 2020"},{"key":"5357_CR16","unstructured":"European Medicines Agency (2018) Bondronat (ibandronic acid): summary of product characteristics. https:\/\/www.ema.europa.eu\/documents\/product-information\/bondronat-epar-product-information_en.pdf. Accessed 30 Jan 2020"},{"key":"5357_CR17","unstructured":"Medicines.org (2017) Pamidronate disodium 9 mg\/ml sterile concentrate. https:\/\/www.medicines.org.uk\/emc\/medicine\/21443. Accessed 30 Jan 2020"},{"key":"5357_CR18","unstructured":"Medicines.org (2017) Bonefos capsules. https:\/\/www.medicines.org.uk\/emc\/product\/899\/smpc. Accessed 30 Jan 2020"},{"issue":"27","key":"5357_CR19","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.2174\/138161210793563635","volume":"16","author":"J Roelofs","year":"2010","unstructured":"Roelofs J, Thompson K, Ebetino H, Rogers J, Coxon P (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950\u20132960","journal-title":"Curr Pharm Des"},{"issue":"9","key":"5357_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"5357_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrclinonc.2011.197","volume":"9","author":"JE Brown","year":"2012","unstructured":"Brown JE, Coleman RE (2012) Denosumab in patients with cancer\u2014a surgical strike against the osteoclast. Nat Rev Clin Oncol 9(2):110\u2013118","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"5357_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2):75\u201385","journal-title":"Bone"},{"issue":"16","key":"5357_CR23","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"issue":"19","key":"5357_CR24","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"5357_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","volume":"9","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Pu F, Shao Z (2017) The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. J Bone Oncol 9:21\u201324. https:\/\/doi.org\/10.1016\/j.jbo.2017.09.003","journal-title":"J Bone Oncol"},{"issue":"35","key":"5357_CR26","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/jco.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132\u20135139. https:\/\/doi.org\/10.1200\/jco.2010.29.7101","journal-title":"J Clin Oncol"},{"issue":"9768","key":"5357_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822. https:\/\/doi.org\/10.1016\/s0140-6736(10)62344-6","journal-title":"Lancet"},{"issue":"9","key":"5357_CR28","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/jco.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125\u20131132. https:\/\/doi.org\/10.1200\/jco.2010.31.3304","journal-title":"J Clin Oncol"},{"issue":"12","key":"5357_CR29","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00520-013-1932-2","volume":"21","author":"R Von Moos","year":"2013","unstructured":"Von Moos R, Body J, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21(12):3497\u20133507","journal-title":"Support Care Cancer"},{"issue":"Supplement 2","key":"5357_CR30","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1513\/AnnalsATS.201309-298RM","volume":"11","author":"GW Wong","year":"2014","unstructured":"Wong GW, Miravitlles M, Chisholm A, Krishnan JA (2014) Respiratory guidelines\u2014which real world? Ann Am Thorac Soc 11(Supplement 2):S85\u2013S91","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"5357_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487\u2013497","journal-title":"N Engl J Med"},{"issue":"1","key":"5357_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00213.x","journal-title":"Value Health"},{"issue":"10","key":"5357_CR33","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s00520-014-2251-y","volume":"22","author":"RK Hernandez","year":"2014","unstructured":"Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J, Liede A (2014) Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer 22(10):2697\u20132705","journal-title":"Support Care Cancer"},{"issue":"6","key":"5357_CR34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00520-017-3583-1","volume":"25","author":"Y Qian","year":"2017","unstructured":"Qian Y, Bhowmik D, Kachru N, Hernandez RK (2017) Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer 25(6):1845\u20131851","journal-title":"Support Care Cancer"},{"issue":"1","key":"5357_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jval.2014.10.004","volume":"18","author":"J Arellano","year":"2015","unstructured":"Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, Gatta F, Qian Y (2015) Physicians\u2019 preferences for bone metastases drug therapy in the United States. Value Health 18(1):78\u201383","journal-title":"Value Health"},{"issue":"1","key":"5357_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-014-2309-x","volume":"23","author":"G Hechmati","year":"2015","unstructured":"Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, Haynes I, Bahl A, von Moos R, Body J-J (2015) Patients\u2019 preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer 23(1):21\u201328","journal-title":"Support Care Cancer"},{"key":"5357_CR37","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1053\/j.seminoncol.2010.06.006","volume":"37","author":"JE Mortimer","year":"2010","unstructured":"Mortimer JE, Pal SK (2010) Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol 37:S66\u2013S72","journal-title":"Semin Oncol"},{"issue":"1","key":"5357_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR Jr, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. Jama 317(1):48\u201358. https:\/\/doi.org\/10.1001\/jama.2016.19425","journal-title":"Jama"},{"issue":"7","key":"5357_CR39","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3(7):906\u2013912. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6316","journal-title":"JAMA Oncol"},{"key":"5357_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.11.004","volume":"11","author":"R von Moos","year":"2018","unstructured":"von Moos R, Body J-J, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y (2018) Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries. J Bone Oncol 11:1\u20139. https:\/\/doi.org\/10.1016\/j.jbo.2017.11.004","journal-title":"J Bone Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05357-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T01:53:26Z","timestamp":1613786006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05357-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5357"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05357-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was conducted by Vilua Healthcare with funding provided by Amgen (Europe) GmbH. ID has received consulting and lecture honoraria from Amgen, and lecture honoraria from AstraZeneca, Riemser, Roche and TEVA. SA was an employee of Vilua Healthcare (formerly Arvato Health Analytics) GmbH at the time of the study, which received funding from Amgen GmbH. CG is an employee of Amgen. MI and DH were employees of Amgen at the time of the study. DN is an employee of Amgen and holds Amgen stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}